Figure 3.
Graphic correlation of percent reduction in major coronary events to percent LDL-C lowering based on published data from major secondary prevention trials. Notably, statin trials are distributed along a steeper line than non-statin trials, suggesting contribution from statins’ pleiotropic effects on CV outcomes beyond pure LDL-C lowering.